Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis. The company's lead product candidate is mizagliflozin, an orally administered, small molecule drug candidate being developed for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome.
前收盘价
US$32.50
−US$1.63 · -4.78%
盘中时间采用ET。市场数据可能有所延迟。
Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis. The company's lead product candidate is mizagliflozin, an orally administered, small molecule drug candidate being developed for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome.
日内区间
当前US$32.50
52周区间
当前US$32.50
报告持有此股票敞口的交易所交易基金。
Vanguard Russell 2000 ETFVTWO
Vanguard Russell 2000 Growth ETFVTWG
Vanguard Russell 2000 Value ETFVTWV
Vanguard Russell 3000 ETFVTHRAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
